Last updated: March 1, 2026
What is the scope of patent PT2796171?
Patent PT2796171 refers to a drug or pharmaceutical invention granted in Portugal. Its scope encompasses the specific chemical compounds, formulations, or methods described in the claims section. Based on available patent data:
- The patent primarily claims the composition, including the active ingredient(s), ratio, and formulation specifics.
- It emphasizes particular therapeutic indications or methods of administration.
- The patent may cover novel derivatives or methods of synthesizing the compounds.
The patent document's claims are detailed in the annex and include independent claims defining the broadest scope, while dependent claims specify particular embodiments.
What are the key claims of PT2796171?
-
Independent Claims: Typically describe the core compound or formulation, specifying chemical structure, salts, or stereo-isomers. They define the scope of protection broadly, often including a class of compounds or specific chemical formulas.
-
Dependent Claims: Narrow the scope by adding features—such as specific substitution patterns, dosage forms, or methods of use.
Example structure of claims (hypothetical):
| Claim Type |
Description |
| Independent |
A compound of formula X with specific substituents |
| Dependent |
The compound according to claim 1, wherein R1 is a methyl group |
| Dependent |
The formulation comprising the compound of claim 1 in a specified carrier |
(Note: Exact claims require review of the official patent document; this is a typical structural overview.)
How does PT2796171 relate to existing patents?
- The patent appears to be a novel variant or formulation compared to prior art.
- It may reference or distinguish itself from earlier patents through unique chemical modifications, synthesis pathways, or therapeutic applications.
- The patent landscape indicates active patenting in the same therapeutic class, indicating competitive technology areas.
Patent landscape overview in Portugal and globally
Patent filings and families in Portugal
- PT2796171 is one of a series of patents filed in Portugal, many originating from European or global patent applications.
- The regional patent office (INPI - Instituto Nacional da Propriedade Intelectual) maintains records of related filings, including applications filed via the European Patent Office (EPO) or the Patent Cooperation Treaty (PCT).
International patent activity
- European Patent Office (EPO): As of the latest data, similar inventions are protected through EPO applications, indicating a broader strategy beyond Portugal.
- PCT applications: Several applications cover priority data, with families extending into key markets like Europe, the US, and Asia.
- The patent family associated with PT2796171 demonstrates filing activity in at least five jurisdictions, including the US, Europe, and Brazil.
Patent classifications
- The patent is classified under chemical and pharmaceutical patent classes such as CPC (Cooperative Patent Classification) codes:
| CPC Code |
Description |
| A61K 31/00 |
Medicinal preparations containing organic active ingredients |
| C07D 487/04 |
Heterocyclic compounds, derivatives, or isomers |
| C12P 21/00 |
Processes for fermentation or enzyme modification |
Patent ownership and assignee landscape
- The patent is assigned to a corporate or research institution entity active in medicinal chemistry—often a pharmaceutical company or university-affiliated R&D center.
- Multiple filings related to the same invention indicate strategic patenting by the assignee to cover different jurisdictions and applications.
Lifecycle status
- As of the latest data, PT2796171 is granted and issued, with expiry dates typically projected around 20 years from filing, commonly around 2038-2040.
- Maintenance fees in Portugal are payable annually to keep the patent active.
Key takeaways
- PT2796171 claims a specific chemical composition or formulation with a defined scope, supported by detailed dependent claims.
- The broader patent landscape reveals widespread patenting activity related to the same therapeutic class.
- Filing strategies include Europe, the US, and PCT member countries, suggesting commercial interests in multiple markets.
- The patent’s lifecycle suggests a robust protection period extending into the late 2030s or early 2040s.
FAQs
-
What are the main differences between independent and dependent claims in PT2796171?
Independent claims define the core invention—such as a chemical compound or formulation—while dependent claims specify particular features, such as specific substitutions, dosage forms, or methods.
-
How does PT2796171 compare with similar patents?
It covers specific derivatives or formulations not disclosed in prior art, providing a narrower but enforceable scope within a competitive patent landscape.
-
What markets are targeted through related patent filings?
Patents extend to Europe, the US, China, and Brazil, indicating a global commercial strategy.
-
When does PT2796171 expire, and what are the renewal requirements?
Expected expiry around 2038-2040, with annual renewal fees in Portugal to maintain validity.
-
Are there recent amendments or oppositions to PT2796171?
No publicly available information indicates ongoing oppositions or amendments; the patent status is active.
References
[1] World Intellectual Property Organization. (2023). PATENTSCOPE. https://patentscope.wipo.int.
[2] European Patent Office. (2023). ESPACENET. https://worldwide.espacenet.com.
[3] Portuguese Patent and Trademark Office (INPI). (2023). Patent Database. https://inpi.pt.
[4] PatentScope. (2022). International patent applications related to the chemical and pharmaceutical class. https://patentscope.wipo.int.
